Interface Biologics Announces New V.P., Business Development
TORONTO, Dec. 04, 2018 (GLOBE NEWSWIRE) — Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the addition of Kelley Dealhoy, to the IBI management team, as Vice President of Business Development.
Kelley has had a distinguished career with over twenty-five years of experience in the life science sector; the last 15 years dedicated to structuring, implementing and overseeing pharmaceutical partnerships to drive innovation. Prior to joining IBI, Kelley held leadership roles in R&D and business development at leading Pharmaceutical companies including Eli Lilly, Merck and Novartis. Most recently she was a Life Science advisor in Deloitte’s Financial Advisory (M&A) practice where she worked with Biotech and Pharmaceutical companies to develop and implement strategies to drive growth and unlock value.
“We are very pleased that Kelley has chosen to join our team,” commented Tom Reeves, President and C.E.O. of Interface Biologics, Inc. “Her depth of experience in biotech/pharma is critical to our go-forward strategy and her interest in joining our organization underscores the strength of IBI’s value proposition. She is joining at a perfect time for us as our recently announced FDA agreement on a 505(b)(2) pathway for our sustained release dexamethasone intravitreal implant combined with our strong pre-clinical data provides a strong platform for discussions with potential partners.”
“It is an honor to have the opportunity to join IBI given their strong track record of successfully innovating and commercializing materials in Medtech,” stated Kelley Dealhoy, new Vice President of Business Development at Interface Biologics, Inc. “It is especially exciting to join at this time as IBI expands into drug delivery with the potential to address debilitating conditions such as posterior inflammatory eye diseases including diabetic macular edema, retinal vein occlusion and non-infectious uveitis with the IBE-814 IVT implant.”
About Interface Biologics, Inc. Interface Biologics (IBI) is an early commercial stage privately held company that develops innovative materials for Medtech and Pharmaceutical applications. IBI surface modification additives are used in FDA-approved medical devices and are clinically proven to reduce infection and thrombus-related complications. IBI’s sustained local drug delivery technology is applicable across a range of drug classes and medical specialties with an initial focus on ophthalmology. www.interfacebiologics.com
Julie Fotheringham, Partner, Hageman Communications
M: 416-951-7988 E: Julie.firstname.lastname@example.org